Latest news with #IMTX
Business Insider
3 days ago
- Business
- Business Insider
Immatics announces presentation of data from ongoing Phase 1b trial on IMA203
Immatics (IMTX) announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor. The most frequent treatment-emergent adverse events were anticipated cytopenias associated with lymphodepletion. Expected and manageable cytokine release syndrome was mostly Grades 1 and 2, which is consistent with the mechanism of action. The expected median PFS in this post-checkpoint inhibitor patient population6 is 2-3 months, and the IMA203 Phase 1b data presented today at ASCO indicate a continued median PFS of greater than or equal to 6 months. Confident Investing Starts Here:
Yahoo
13-05-2025
- Business
- Yahoo
Immatics: Q1 Earnings Snapshot
TUBINGEN, Germany (AP) — TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Tuesday reported a loss of $41.9 million in its first quarter. The Tubingen, Germany-based company said it had a loss of 35 cents per share. The company posted revenue of $19.5 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on IMTX at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
13-05-2025
- Business
- San Francisco Chronicle
Immatics: Q1 Earnings Snapshot
TUBINGEN, Germany (AP) — TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Tuesday reported a loss of $41.9 million in its first quarter. The Tubingen, Germany-based company said it had a loss of 35 cents per share. The company posted revenue of $19.5 million in the period. _____
Washington Post
13-05-2025
- Business
- Washington Post
Immatics: Q1 Earnings Snapshot
TUBINGEN, Germany — TUBINGEN, Germany — Immatics N.V. (IMTX) on Tuesday reported a loss of $41.9 million in its first quarter. The Tubingen, Germany-based company said it had a loss of 35 cents per share. The company posted revenue of $19.5 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on IMTX at
